Oryzon Genomics (ORY) Q1 2025 earnings summary

Executive summary

• Completed €30 million capital increase, oversubscribed and anchored by a US institutional investor, strengthening cash position for R&D and corporate initiatives.

• Awarded €13.26 million non-refundable EU grant under the Med4Cure IPCEI for the VANDAM project, supporting CNS and oncology R&D.

• Advanced clinical pipeline: finalizing Phase III vafidemstat trial in BPD, ongoing Phase IIb in schizophrenia, and multiple oncology trials with iadademstat.

• Published results from PMS observational study, supporting future precision psychiatry trials.

Financial highlights

• Net loss of $1.6 million for Q1 2025, compared to $1.1 million in Q1 2024.

• Negative net result of $1.8 million (-$0.03/share) for Q1 2025, versus -$1.2 million (-$0.02/share) in Q1 2024.

• R&D expenses were $2.6 million, stable year-over-year; G&A expenses increased to $1.2 million from $0.9 million.

• Cash and cash equivalents at $4.1 million as of March 31, 2025, down from $11.6 million a year earlier.

• Total assets at $116.1 million and stockholders' equity at $92.3 million as of March 31, 2025.

Outlook and guidance

• Preparing to submit Phase III PORTICO-2 protocol for vafidemstat in BPD to FDA in 1H2025; trial aims for 350 patients over 18 weeks.

• Ongoing recruitment in EVOLUTION Phase IIb trial in schizophrenia; exploring further precision medicine trials in autism spectrum and related disorders.

• Oncology pipeline progressing with multiple Phase I/II trials in SCLC, AML, and MDS; data updates expected at ASH-2025.

• Solid cash position post-financing and grant to support execution of R&D programs.